Меню
Идёт набор NCT05825261

Exploring Novel Biomarkers for Emphysema Detection

Наблюдательное Copd Emphysema

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: voice sampling, capnometry.
Кому может быть актуально
Состояния в реестре: Copd, Emphysema. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Нидерланды
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Exploring Novel Biomarkers for Emphysema Detection: the ENBED Study

Обзор

The goal of this clinical trial is to evaluate whether voice or capnometry, alone or in combination with other (non invasive) biomarkers can be used to detect emphysema on chest CT-scan in people with chronic obstructive pulmonary disease (COPD). The main question it aims to answer is: • Can a machine-learning based algorithm be developed that can classify the extent of emphysema on chest CT scan from patients with COPD, based on voice and/or capnometry. Participants will: * perform different voice-related tasks * perform capnometry twice (before/after exercise) * perform a light exercise task between tasks ( 5-sit-to-stand test) * undergo one venipuncture

Подробное описание

This is a cross sectional, single center study. At the clinic, patients with COPD will be invited to perform several voice related tasks (paced reading, sustained vowels, cough, quiet breathing) and will be instructed to perform capnometry measurements. These measurements will be performed before and after a light exercise task (5-STS: 5-sit-to-stand test).

Clinical characterisation of patients including pulmonary function tests (spirometry, body plethysmography, diffusion capacity) and CT scans have been performed in all patients as a part of routine workup in the COPD care pathway. Emphysema will be quantified as low attenuation areas with a density below -950 Hounsfield units (HU) using Syngovia (Siemens, Erlangen, Germany).

The primary outcome will fit a simple machine learning classification model (e.g. using logistic regression, support vector machines, random forests and/or decision tree) to classify logistic regression model for the outcome of emphysema (\>25% vs ≤ 25%) from speech features and capnometry. with explanatory variables of speech features. Similar classification methods with incremental models using capnography features will be explored. Prior to carrying out the above analyses, data has to be pre-processed, including merging data, quality control, handling of missing data and feature extraction.

Вмешательства

  • Другое voice sampling
    Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
  • Другое capnometry
    Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated

Первичные конечные точки

  • percentage of participants having moderate to severe emphysema on a chest CT (defined as > 25%) [Срок оценки: baseline]
  • number of (non-linguistic) inhalations per syllable from sustained vowel [Срок оценки: baseline]
  • harmonics-to-noise-ratio from sustained vowel [Срок оценки: baseline]
  • vowel duration from sustained vowel [Срок оценки: baseline]
  • shimmer from sustained vowel [Срок оценки: baseline]
  • end-tidal CO2 from capnography (ETCO2) [Срок оценки: baseline]
  • phase-2 slope from capnography (slp2) [Срок оценки: baseline]
  • phase-2 slope from capnography (slp3) [Срок оценки: baseline]
Вторичные конечные точки (4)
  • serum sRAGE [Срок оценки: baseline]
  • ratio of residual volume to total lung capacity (RV/TLC) on body plethysmography [Срок оценки: baseline]
  • diffusion capacity of the lungs for carbon monoxide [Срок оценки: baseline]
  • forced expiratory volume in one second [Срок оценки: baseline]

Критерии участия

Критерии включения

  • Adults aged over 18 years
  • current respiratory smptoms (any dyspnea, cough or sputum)
  • spirometry confirmed diagnosis of a non-fully reversible airflow obstruction, defined as a post bronchodilator Forced Expiratory Volume at one second/Forced Vital Capacity (FEV1/FVC ratio) < 0.7 and/or emphysemateus abnormalities on CT imaging.
  • presence of risk factors or causes associated with COPD
  • chest CT scan performed in the past 12 months prior to inclusion to the study
  • able to understand, read and write Dutch language

Критерии исключения

  • acute exacerbation of COPD within 8 weeks of start of the study
  • comorbidities affecting speech or breathing coordination (neuromuscular disease, CVA< BMI > 40)
  • comorbidities affecting speech characteristics of dyspnea (severe heart failure, interstitial lung disease)
  • comorbidities affecting respiratory system including but not exclusive to asthma or cystic fibrosis
  • comorbidities that significantly interfere with interpretation of speech (audio signals), such as Parkinson's disease, bulbar palsy, or vocal cord paralysis.
  • Medical history of lobectomy or endoscopic lung volume reduction (ELVR)
  • inability to carry out a capnography recording.
  • investigator's uncertainty about the willingness or ability of the patients to comply with the protocol requirements.
  • participation in another study involving investigational products. Participation in observational studies is allowed.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Только случаи

Центры проведения

Нидерланды · 2 центра
  • Dept of Respiratory Medicine, Maastricht University Medical Centre — Maastricht
  • Laurentius Ziekenhuis — Roermond

Идентификаторы

NCT: NCT05825261 · NL83173.068.22/METC22-071

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗